About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Publications
Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two Phase III studies
Publications
Glucocorticoid sparing effect of Janus Kinase inhibitors compared to biological Disease Modifying Anti-Rheumatic Drugs in rheumatoid arthritis: A single-centre retrospective analysis
Publications
Enhanced type 1 interferon signature in axial spondyloarthritis patients unresponsive to secukinumab treatment
Publications
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment
Publications
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Publications
Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: Results from the Phase 3 ELEVATE UC clinical programme
Publications
Effects of mirikizumab on histologic resolution of Crohn's sisease in a randomised controlled Phase 2 trial
Publications
Efficacy and Safety of Bimekizumab in Patients with Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies
Publications
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial
Publications
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
Publications
Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease
Publications
Pregnancy outcomes in patients treated with upadacitinib: Analysis of data from clinical trials and postmarketing reports
Publications
Efficacy and safety of filgotinib for the treatment of perianal fistulising Crohn’s disease [DIVERGENCE 2]: A Phase 2, randomised, placebo-controlled trial
Publications
Risankizumab induction therapy achieves early symptom improvements that are associated with future clinical and endoscopic outcomes in Crohn's disease: Post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 studies
Publications
Patients with high baseline neutrophil-to-lymphocyte ratio exhibit better response to filgotinib as treatment for rheumatoid arthritis
Publications
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials
Publications
Tofacitinib in acute severe ulcerative colitis (TACOS): A randomized controlled trial
Publications
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of Phase 2/3 randomized trials
Publications
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER)
Publications
Deucravacitinib onset of action and maintenance of response in Phase 3 plaque psoriasis trials
Publications
Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial
Publications
Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry
Publications
Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: Results from parts II and III of a randomized active-comparator-controlled Phase IIIb trial (POLARIS)
Publications
Efficacy and safety of ustekinumab for ulcerative colitis through 4 years: Final results of the UNIFI long-term maintenance study
Publications
Maintenance risankizumab sustains induction response in patients with Crohn’s disease in a randomized Phase 3 trial
Publications
The outcomes of children born to mothers with autoimmune rheumatic diseases
Publications
Durable Control of Psoriatic Arthritis with Guselkumab Across Domains and Patient Characteristics: Post Hoc Analysis of a Phase 3 study
Publications
A disease-associated gene desert directs macrophage inflammation through ETS2
Publications
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: Results from two Phase 3 studies
Publications
Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study
Publications
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the Phase 3, randomised SELECT-COMPARE study
Publications